MaliTuberculosis profile
Population  2015 18 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.7 (0.99–2.5) 9.4 (5.6–14)
Mortality (HIV+TB only) 0.44 (0.28–0.64) 2.5 (1.6–3.7)
Incidence  (includes HIV+TB) 10 (6.5–14) 57 (37–81)
Incidence (HIV+TB only) 1.4 (0.85–2) 7.7 (4.8–11)
Incidence (MDR/RR-TB)** 0.61 (0.14–1.1) 3.5 (0.8–6.3)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.6 (0.3–0.9) 3.1 (1.1–5.1) 3.7 (1.4–6)
Males 0.5 (0.3–0.71) 5.9 (4–7.7) 6.4 (4.3–8.4)
Total 1.1 (0.71–1.5) 8.9 (6.8–11) 10 (6.5–14)
TB case notifications, 2015  
Total cases notified 7 015
Total new and relapse 5 998
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 67%
          - % pulmonary 79%
          - % bacteriologically confirmed among pulmonary 100%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 60% (42–92)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.22 (0.12–0.36)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 544 13%
          - on antiretroviral therapy 465 85%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  380
(96–670)
Estimated % of TB cases with MDR/RR-TB 2.8% (0.1–6.7) 21% (2.2–39)  
% notified tested for rifampicin resistance 2% 22% 381
MDR/RR-TB cases tested for resistance to second-line drugs   10
Laboratory-confirmed cases MDR/RR-TB: 30, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 30, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 73% 5 177
Previously treated cases, excluding relapse, registered in 2014 70% 789
HIV-positive TB cases, all types, registered in 2014 57% 240
MDR/RR-TB cases started on second-line treatment in 2013 42% 12
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
3.4% (3.1–3.7)
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data